Development and Validation of a Circulating Tumor DNA Detection Technique in Patients With Ovarian Cancer
Technique development:
In a first step, the different available techniques will be evaluated for specificity and
sensibility using serial dilutions of cell lines with or without TP53 mutation.
Validation:
The tumor DNA detection rate will be estimated from patient's blood with ovarian cancer.
The investigators will study 25 patients to obtain at least 15 patients bearing a TP53
mutation that could be characterized in the primitive tumor or metastasis. With those 15
patients, the investigators will determine the most sensitive technique and the best
cost/efficiency ratio.
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label
Assessment and development of circulating tumor DNA detection techniques
Quantification of circulating tumor DNA in blood samples. Results expressed in number of samples where circulating DNA is present.
2 years
No
LANTZ Olivier, MD
Principal Investigator
Institut Curie
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
IC2010-03
NCT01350908
April 2011
April 2012
Name | Location |
---|